Alan McCool, MD
Urology · Jasper, ALNPI 1811940679
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.2%), other and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Integra Lifesciences Corporation at 27.4% of the total. Reporting peaked in 2024 at $3,145 and has fallen 60.3% since, to $1,250 in 2025.
Across 170 payments — averaging $42.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Integra Lifesciences Corporation$2K
- Coloplast$1K
- Medtronic$1K
- Axonics, Inc.$968
- Boston Scientific$468
- Olympus America Inc.$258
- plus $794 from 18 others
What the payments were for
- Speaking & faculty fees$2734%
- Food & beverage$4,12557%
- Education$6739%
- Gifts$1652%
- Other$1,98027%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Integra Lifesciences Corporation | 1 | $1,980 |
| Coloplast | 47 | $1,492 |
| Medtronic(2 entities) | 35 | $1,256 |
| Axonics, Inc. | 22 | $968 |
| Boston Scientific | 19 | $468 |
| Olympus America Inc. | 14 | $258 |
| Intuitive Surgical | 2 | $234 |
| Astellas Pharma US Inc | 1 | $100 |
| Johnson & Johnson | 4 | $82 |
| Conmed Corporation | 2 | $48 |
| Ferring Pharmaceuticals Inc. | 2 | $45 |
| AstraZeneca | 1 | $35 |
| Calyxo, Inc. | 1 | $32 |
| Teleflex LLC | 1 | $27 |
| Urogen Pharma, Inc. | 1 | $24 |
| Myriad Genetic Laboratories, Inc. | 1 | $24 |
| Bluewind Medical | 1 | $24 |
| Travere Therapeutics, Inc. | 9 | $19 |
| Pfizer | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Procept Biorobotics Corporation | 1 | $18 |
| ABC Home Medical Supply, Inc. | 1 | $16 |
| Ambu Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,215 in reported general payments places this provider in the 75th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 110 | $85,072 |
| MyrbetriqMirabegron | 44 | $29,671 |
| Estradiol | 72 | $8,618 |
| Testosterone Cypionate | 186 | $7,703 |
| Solifenacin Succinate | 104 | $7,116 |
| LinzessLinaclotide | 11 | $5,869 |
| Methenamine Hippurate | 106 | $5,663 |
| Tamsulosin Hcl | 382 | $4,881 |
| Silodosin | 25 | $3,087 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 54 | $2,755 |
| ImvexxyEstradiol | 11 | $2,331 |
| Oxybutynin Chloride ErOxybutynin Chloride | 40 | $2,181 |
| Finasteride | 176 | $2,178 |
| Gentamicin Sulfate | 55 | $1,600 |
| Imipramine Hcl | 24 | $1,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $100 | $29,67144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 179 urology providers in Alabama.
Other urology in Jasper
- Thomas ChiBirmingham$463K
- Joel FunkBirmingham$347K
- Adam BaumgartenBirmingham$271K
- Brian ChristineHomewood$215K
- Vincent BivinsHomewood$117K
- Kyle WoodBirmingham$91K
- Christopher KeelFairhope$68K
- Rachel EngelbergHomewood$61K
- Jeffrey NixBirmingham$54K
- Tracey WilsonBirmingham$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.